Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 119

1.

Imidazo[2,1-a]isoindole scaffold as an uncharted structure active on Leishmania donovani.

Arsène S, Gómez-Pérez V, Escarcena R, Abengózar MÁ, García-Hernández R, Nácher-Vázquez M, San Feliciano A, Gamarro F, Rivas L, Olmo ED.

Eur J Med Chem. 2019 Jul 29;182:111568. doi: 10.1016/j.ejmech.2019.111568. [Epub ahead of print]

PMID:
31419778
2.

Thiol-ene "Click" Synthesis and Pharmacological Evaluation of C-Glycoside sp2-Iminosugar Glycolipids.

Sánchez-Fernández EM, García-Moreno MI, García-Hernández R, Padrón JM, García Fernández JM, Gamarro F, Ortiz Mellet C.

Molecules. 2019 Aug 8;24(16). pii: E2882. doi: 10.3390/molecules24162882.

3.

4-Aminoquinoline-based compounds as antileishmanial agents that inhibit the energy metabolism of Leishmania.

Manzano JI, Konstantinović J, Scaccabarozzi D, Perea A, Pavić A, Cavicchini L, Basilico N, Gamarro F, Šolaja BA.

Eur J Med Chem. 2019 Jul 5;180:28-40. doi: 10.1016/j.ejmech.2019.07.010. [Epub ahead of print]

PMID:
31299585
4.

Complete assembly of the Leishmania donovani (HU3 strain) genome and transcriptome annotation.

Camacho E, González-de la Fuente S, Rastrojo A, Peiró-Pastor R, Solana JC, Tabera L, Gamarro F, Carrasco-Ramiro F, Requena JM, Aguado B.

Sci Rep. 2019 Apr 16;9(1):6127. doi: 10.1038/s41598-019-42511-4.

5.

Evaluation of a class of isatinoids identified from a high-throughput screen of human kinase inhibitors as anti-Sleeping Sickness agents.

Klug DM, Diaz-Gonzalez R, Pérez-Moreno G, Ceballos-Pérez G, García-Hernández R, Gomez-Pérez V, Ruiz-Pérez LM, Rojas-Barros DI, Gamarro F, González-Pacanowska D, Martínez-Martínez MS, Manzano P, Ferrins L, Caffrey CR, Navarro M, Pollastri MP.

PLoS Negl Trop Dis. 2019 Feb 8;13(2):e0007129. doi: 10.1371/journal.pntd.0007129. eCollection 2019 Feb.

6.

Genomic and transcriptomic alterations in Leishmania donovani lines experimentally resistant to antileishmanial drugs.

Rastrojo A, García-Hernández R, Vargas P, Camacho E, Corvo L, Imamura H, Dujardin JC, Castanys S, Aguado B, Gamarro F, Requena JM.

Int J Parasitol Drugs Drug Resist. 2018 Aug;8(2):246-264. doi: 10.1016/j.ijpddr.2018.04.002. Epub 2018 Apr 13.

7.

Functional role of highly conserved residues of the N-terminal tail and first transmembrane segment of a P4-ATPase.

Perandrés-López R, Sánchez-Cañete MP, Gamarro F, Castanys S.

Biochem J. 2018 Mar 6;475(5):887-899. doi: 10.1042/BCJ20170749.

PMID:
29438067
8.

Drug resistance and treatment failure in leishmaniasis: A 21st century challenge.

Ponte-Sucre A, Gamarro F, Dujardin JC, Barrett MP, López-Vélez R, García-Hernández R, Pountain AW, Mwenechanya R, Papadopoulou B.

PLoS Negl Trop Dis. 2017 Dec 14;11(12):e0006052. doi: 10.1371/journal.pntd.0006052. eCollection 2017 Dec. Review.

9.

Leishmania LABCG2 transporter is involved in ATP-dependent transport of thiols.

Perea A, Manzano JI, Kimura Y, Ueda K, Castanys S, Gamarro F.

Biochem J. 2018 Jan 2;475(1):87-97. doi: 10.1042/BCJ20170685.

PMID:
29162656
10.

ABCI3 Is a New Mitochondrial ABC Transporter from Leishmania major Involved in Susceptibility to Antimonials and Infectivity.

Arcari T, Manzano JI, Gamarro F.

Antimicrob Agents Chemother. 2017 Nov 22;61(12). pii: e01115-17. doi: 10.1128/AAC.01115-17. Print 2017 Dec.

11.

Novel 1,2-dihydroquinazolin-2-ones: Design, synthesis, and biological evaluation against Trypanosoma brucei.

Pham T, Walden M, Butler C, Diaz-Gonzalez R, Pérez-Moreno G, Ceballos-Pérez G, Gomez-Pérez V, García-Hernández R, Zecca H, Krakoff E, Kopec B, Ichire O, Mackenzie C, Pitot M, Ruiz LM, Gamarro F, González-Pacanowska D, Navarro M, Dounay AB.

Bioorg Med Chem Lett. 2017 Aug 15;27(16):3629-3635. doi: 10.1016/j.bmcl.2017.07.032. Epub 2017 Jul 11.

12.

Leishmania LABCG1 and LABCG2 transporters are involved in virulence and oxidative stress: functional linkage with autophagy.

Manzano JI, Perea A, León-Guerrero D, Campos-Salinas J, Piacenza L, Castanys S, Gamarro F.

Parasit Vectors. 2017 May 30;10(1):267. doi: 10.1186/s13071-017-2198-1.

13.

Arylthiosemicarbazones as antileishmanial agents.

Manzano JI, Cochet F, Boucherle B, Gómez-Pérez V, Boumendjel A, Gamarro F, Peuchmaur M.

Eur J Med Chem. 2016 Nov 10;123:161-170. doi: 10.1016/j.ejmech.2016.07.014. Epub 2016 Jul 14.

PMID:
27475107
14.

Decreased antimony uptake and overexpression of genes of thiol metabolism are associated with drug resistance in a canine isolate of Leishmania infantum.

Gómez Pérez V, García-Hernandez R, Corpas-López V, Tomás AM, Martín-Sanchez J, Castanys S, Gamarro F.

Int J Parasitol Drugs Drug Resist. 2016 Aug;6(2):133-9. doi: 10.1016/j.ijpddr.2016.04.003. Epub 2016 Jun 4.

15.

Tyrosol and hydroxytyrosol derivatives as antitrypanosomal and antileishmanial agents.

Belmonte-Reche E, Martínez-García M, Peñalver P, Gómez-Pérez V, Lucas R, Gamarro F, Pérez-Victoria JM, Morales JC.

Eur J Med Chem. 2016 Aug 25;119:132-40. doi: 10.1016/j.ejmech.2016.04.047. Epub 2016 Apr 26.

PMID:
27155468
16.

Genomic and Molecular Characterization of Miltefosine Resistance in Leishmania infantum Strains with Either Natural or Acquired Resistance through Experimental Selection of Intracellular Amastigotes.

Mondelaers A, Sanchez-Cañete MP, Hendrickx S, Eberhardt E, Garcia-Hernandez R, Lachaud L, Cotton J, Sanders M, Cuypers B, Imamura H, Dujardin JC, Delputte P, Cos P, Caljon G, Gamarro F, Castanys S, Maes L.

PLoS One. 2016 Apr 28;11(4):e0154101. doi: 10.1371/journal.pone.0154101. eCollection 2016.

17.

The LABCG2 Transporter from the Protozoan Parasite Leishmania Is Involved in Antimony Resistance.

Perea A, Manzano JI, Castanys S, Gamarro F.

Antimicrob Agents Chemother. 2016 May 23;60(6):3489-96. doi: 10.1128/AAC.02813-15. Print 2016 Jun.

18.

Optimization by Molecular Fine Tuning of Dihydro-β-agarofuran Sesquiterpenoids as Reversers of P-Glycoprotein-Mediated Multidrug Resistance.

Callies O, Sánchez-Cañete MP, Gamarro F, Jiménez IA, Castanys S, Bazzocchi IL.

J Med Chem. 2016 Mar 10;59(5):1880-90. doi: 10.1021/acs.jmedchem.5b01429. Epub 2016 Feb 11.

PMID:
26836364
19.

The Oral Antimalarial Drug Tafenoquine Shows Activity against Trypanosoma brucei.

Carvalho L, Martínez-García M, Pérez-Victoria I, Manzano JI, Yardley V, Gamarro F, Pérez-Victoria JM.

Antimicrob Agents Chemother. 2015 Oct;59(10):6151-60. doi: 10.1128/AAC.00879-15. Epub 2015 Jul 20.

20.

Fitness of Leishmania donovani parasites resistant to drug combinations.

García-Hernández R, Gómez-Pérez V, Castanys S, Gamarro F.

PLoS Negl Trop Dis. 2015 Apr 7;9(4):e0003704. doi: 10.1371/journal.pntd.0003704. eCollection 2015 Apr.

21.

Restoration of Chemosensitivity in P-Glycoprotein-Dependent Multidrug-Resistant Cells by Dihydro-β-agarofuran Sesquiterpenes from Celastrus vulcanicola.

Callies O, Sánchez-Cañete MP, Gamarro F, Jiménez IA, Castanys S, Bazzocchi IL.

J Nat Prod. 2015 Apr 24;78(4):736-45. doi: 10.1021/np500903a. Epub 2015 Feb 19.

PMID:
25695368
22.

Experimental resistance to drug combinations in Leishmania donovani: metabolic and phenotypic adaptations.

Berg M, García-Hernández R, Cuypers B, Vanaerschot M, Manzano JI, Poveda JA, Ferragut JA, Castanys S, Dujardin JC, Gamarro F.

Antimicrob Agents Chemother. 2015 Apr;59(4):2242-55. doi: 10.1128/AAC.04231-14. Epub 2015 Feb 2.

23.

Mechanisms of action of substituted β-amino alkanols on Leishmania donovani.

Abengózar MÁ, Bustos LA, García-Hernández R, Fernández de Palencia P, Escarcena R, Castanys S, del Olmo E, Gamarro F, San Feliciano A, Rivas L.

Antimicrob Agents Chemother. 2015 Feb;59(2):1211-8. doi: 10.1128/AAC.04003-14. Epub 2014 Dec 8.

24.

Design, synthesis and anti-leishmanial activity of novel symmetrical bispyridinium cyclophanes.

Gómez-Pérez V, Manzano JI, García-Hernández R, Castanys S, Gamarro F, Campos JM.

Eur J Med Chem. 2015 Jan 7;89:362-9. doi: 10.1016/j.ejmech.2014.10.040. Epub 2014 Oct 16.

PMID:
25462252
25.

High-throughput screening platform for natural product-based drug discovery against 3 neglected tropical diseases: human African trypanosomiasis, leishmaniasis, and Chagas disease.

Annang F, Pérez-Moreno G, García-Hernández R, Cordon-Obras C, Martín J, Tormo JR, Rodríguez L, de Pedro N, Gómez-Pérez V, Valente M, Reyes F, Genilloud O, Vicente F, Castanys S, Ruiz-Pérez LM, Navarro M, Gamarro F, González-Pacanowska D.

J Biomol Screen. 2015 Jan;20(1):82-91. doi: 10.1177/1087057114555846. Epub 2014 Oct 20.

PMID:
25332350
26.

4-amino bis-pyridinium derivatives as novel antileishmanial agents.

Gómez-Pérez V, Manzano JI, García-Hernández R, Castanys S, Campos Rosa JM, Gamarro F.

Antimicrob Agents Chemother. 2014 Jul;58(7):4103-12. doi: 10.1128/AAC.02481-13. Epub 2014 May 5.

27.

Functional role of evolutionarily highly conserved residues, N-glycosylation level and domains of the Leishmania miltefosine transporter-Cdc50 subunit.

García-Sánchez S, Sánchez-Cañete MP, Gamarro F, Castanys S.

Biochem J. 2014 Apr 1;459(1):83-94. doi: 10.1042/BJ20131318.

PMID:
24447089
28.

Identification of specific reversal agents for Leishmania ABCI4-mediated antimony resistance by flavonoid and trolox derivative screening.

Manzano JI, Lecerf-Schmidt F, Lespinasse MA, Di Pietro A, Castanys S, Boumendjel A, Gamarro F.

J Antimicrob Chemother. 2014 Mar;69(3):664-72. doi: 10.1093/jac/dkt407. Epub 2013 Oct 14.

PMID:
24126793
29.

A new ABC half-transporter in Leishmania major is involved in resistance to antimony.

Manzano JI, García-Hernández R, Castanys S, Gamarro F.

Antimicrob Agents Chemother. 2013 Aug;57(8):3719-30. doi: 10.1128/AAC.00211-13. Epub 2013 May 28.

30.

LABCG2, a new ABC transporter implicated in phosphatidylserine exposure, is involved in the infectivity and pathogenicity of Leishmania.

Campos-Salinas J, León-Guerrero D, González-Rey E, Delgado M, Castanys S, Pérez-Victoria JM, Gamarro F.

PLoS Negl Trop Dis. 2013 Apr 25;7(4):e2179. doi: 10.1371/journal.pntd.0002179. Print 2013. Erratum in: PLoS Negl Trop Dis. 2013 Jun;7(6). doi:10.1371/annotation/6a3b1d53-4e80-45a9-8fab-f3fb56a134de.

31.

Leishmania donovani develops resistance to drug combinations.

García-Hernández R, Manzano JI, Castanys S, Gamarro F.

PLoS Negl Trop Dis. 2012;6(12):e1974. doi: 10.1371/journal.pntd.0001974. Epub 2012 Dec 20.

32.

Oxazolo[3,2-a]pyridine. A new structural scaffold for the reversal of multi-drug resistance in Leishmania.

Caballero E, Manzano JI, Puebla P, Castanys S, Gamarro F, San Feliciano A.

Bioorg Med Chem Lett. 2012 Oct 1;22(19):6272-5. doi: 10.1016/j.bmcl.2012.07.100. Epub 2012 Aug 10.

PMID:
22939695
33.

Terpenoids from Maytenus species and assessment of their reversal activity against a multidrug-resistant Leishmania tropica line.

Kennedy ML, Llanos GG, Castanys S, Gamarro F, Bazzocchi IL, Jiménez IA.

Chem Biodivers. 2011 Dec;8(12):2291-8. doi: 10.1002/cbdv.201000356.

PMID:
22162167
34.

Overcoming human P-glycoprotein-dependent multidrug resistance with novel dihydro-β-agarofuran sesquiterpenes.

Perestelo NR, Sánchez-Cañete MP, Gamarro F, Jiménez IA, Castanys S, Bazzocchi IL.

Eur J Med Chem. 2011 Oct;46(10):4915-23. doi: 10.1016/j.ejmech.2011.07.048. Epub 2011 Aug 4.

PMID:
21856049
35.

Uptake of the antileishmania drug tafenoquine follows a sterol-dependent diffusion process in Leishmania.

Manzano JI, Carvalho L, García-Hernández R, Poveda JA, Ferragut JA, Castanys S, Gamarro F.

J Antimicrob Chemother. 2011 Nov;66(11):2562-5. doi: 10.1093/jac/dkr345. Epub 2011 Aug 16.

PMID:
21846675
36.

The 8-aminoquinoline analogue sitamaquine causes oxidative stress in Leishmania donovani promastigotes by targeting succinate dehydrogenase.

Carvalho L, Luque-Ortega JR, López-Martín C, Castanys S, Rivas L, Gamarro F.

Antimicrob Agents Chemother. 2011 Sep;55(9):4204-10. doi: 10.1128/AAC.00520-11. Epub 2011 Jun 13.

37.

Sitamaquine overcomes ABC-mediated resistance to miltefosine and antimony in Leishmania.

Pérez-Victoria JM, Bavchvarov BI, Torrecillas IR, Martínez-García M, López-Martín C, Campillo M, Castanys S, Gamarro F.

Antimicrob Agents Chemother. 2011 Aug;55(8):3838-44. doi: 10.1128/AAC.00065-11. Epub 2011 Jun 6.

38.

A new ATP-binding cassette protein is involved in intracellular haem trafficking in Leishmania.

Campos-Salinas J, Cabello-Donayre M, García-Hernández R, Pérez-Victoria I, Castanys S, Gamarro F, Pérez-Victoria JM.

Mol Microbiol. 2011 Mar;79(6):1430-44. doi: 10.1111/j.1365-2958.2010.07531.x. Epub 2011 Jan 23.

39.

Increased glycolytic ATP synthesis is associated with tafenoquine resistance in Leishmania major.

Manzano JI, Carvalho L, Pérez-Victoria JM, Castanys S, Gamarro F.

Antimicrob Agents Chemother. 2011 Mar;55(3):1045-52. doi: 10.1128/AAC.01545-10. Epub 2011 Jan 3.

40.

Non-reducing trisaccharide fatty acid monoesters: novel detergents in membrane biochemistry.

Pérez-Victoria I, Pérez-Victoria FJ, Roldán-Vargas S, García-Hernández R, Carvalho L, Castanys S, Gamarro F, Morales JC, Pérez-Victoria JM.

Biochim Biophys Acta. 2011 Mar;1808(3):717-26. doi: 10.1016/j.bbamem.2010.11.031. Epub 2010 Dec 3.

41.

Disruption of the lipid-transporting LdMT-LdRos3 complex in Leishmania donovani affects membrane lipid asymmetry but not host cell invasion.

Weingärtner A, Drobot B, Herrmann A, Sánchez-Cañete MP, Gamarro F, Castanys S, Günther Pomorski T.

PLoS One. 2010 Aug 26;5(8):e12443. doi: 10.1371/journal.pone.0012443.

42.

Tafenoquine, an antiplasmodial 8-aminoquinoline, targets leishmania respiratory complex III and induces apoptosis.

Carvalho L, Luque-Ortega JR, Manzano JI, Castanys S, Rivas L, Gamarro F.

Antimicrob Agents Chemother. 2010 Dec;54(12):5344-51. doi: 10.1128/AAC.00790-10. Epub 2010 Sep 13.

43.

Antileishmanial and antitrypanosomal activities of the 8-aminoquinoline tafenoquine.

Yardley V, Gamarro F, Croft SL.

Antimicrob Agents Chemother. 2010 Dec;54(12):5356-8. doi: 10.1128/AAC.00985-10. Epub 2010 Sep 13. Erratum in: Antimicrob Agents Chemother. 2011 Jan;55(1):458.

44.

Leishmanicidal and reversal multidrug resistance constituents from Aeonium lindleyi.

Kennedy ML, Cortés F, Piñero JE, Castanys S, López-Arencibia A, Gamarro F, Bazzocchi IL, Jiménez IA.

Planta Med. 2011 Jan;77(1):77-80. doi: 10.1055/s-0030-1250144. Epub 2010 Jul 21.

PMID:
20665372
45.

CDC50A plays a key role in the uptake of the anticancer drug perifosine in human carcinoma cells.

Muñoz-Martínez F, Torres C, Castanys S, Gamarro F.

Biochem Pharmacol. 2010 Sep 15;80(6):793-800. doi: 10.1016/j.bcp.2010.05.017. Epub 2010 May 25.

PMID:
20510206
46.

Novel dihydro-beta-agarofuran sesquiterpenes as potent modulators of human P-glycoprotein dependent multidrug resistance.

Torres-Romero D, Muñoz-Martínez F, Jiménez IA, Castanys S, Gamarro F, Bazzocchi IL.

Org Biomol Chem. 2009 Dec 21;7(24):5166-72. doi: 10.1039/b915678j. Epub 2009 Oct 15.

PMID:
20024113
47.

Low plasma membrane expression of the miltefosine transport complex renders Leishmania braziliensis refractory to the drug.

Sánchez-Cañete MP, Carvalho L, Pérez-Victoria FJ, Gamarro F, Castanys S.

Antimicrob Agents Chemother. 2009 Apr;53(4):1305-13. doi: 10.1128/AAC.01694-08. Epub 2009 Feb 2.

48.

Bis-pyranobenzoquinones as a new family of reversal agents of the multidrug resistance phenotype mediated by P-glycoprotein in mammalian cells and the protozoan parasite Leishmania.

Jiménez-Alonso S, Pérez-Lomas AL, Estévez-Braun A, Muñoz Martinez F, Chávez Orellana H, Ravelo AG, Gamarro F, Castanys S, López M.

J Med Chem. 2008 Nov 27;51(22):7132-43. doi: 10.1021/jm800403b.

PMID:
18954040
49.

Sitamaquine sensitivity in Leishmania species is not mediated by drug accumulation in acidocalcisomes.

López-Martín C, Pérez-Victoria JM, Carvalho L, Castanys S, Gamarro F.

Antimicrob Agents Chemother. 2008 Nov;52(11):4030-6. doi: 10.1128/AAC.00964-08. Epub 2008 Sep 15.

50.

Characterization of an ABCG-like transporter from the protozoan parasite Leishmania with a role in drug resistance and transbilayer lipid movement.

Castanys-Muñoz E, Pérez-Victoria JM, Gamarro F, Castanys S.

Antimicrob Agents Chemother. 2008 Oct;52(10):3573-9. doi: 10.1128/AAC.00587-08. Epub 2008 Jul 21.

Supplemental Content

Loading ...
Support Center